GlobeNewswire

Compuware ThruPut Manager Empowers Next-Generation IT Staff to Optimize Mainframe Batch Execution

Dela

New Visually Intuitive Insight into Workload Scheduling Helps Enterprises Ensure Performance of Critical Back-End Systems While Controlling Costs

 
  • Enterprises must ensure that critical mainframe batch workloads 1) are completed on time, 2) stay within cost parameters and 3) don't interfere with real-time processing that supports digital customer engagement.

  • Batch management can be jeopardized as mainframe responsibilities are transferred to a new generation of IT staff with far less platform experience, and as mainframe environments become increasingly complex.
     
  • ThruPut Manager and its new web interface address these core operational issues by providing IT staff with intuitive, actionable insight into how batch jobs are being initiated and executed, as well as their impact on cost. 

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today released a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

By implementing ThruPut Manager, enterprises can better safeguard performance of both batch and non-batch applications, while avoiding the significant adverse economic impact of preventable spikes in utilization as measured by Rolling 4-Hour Averages (R4HA), the metric upon which IBM bases its software licensing fees.

Additionally, with ThruPut Manager, enterprises can successfully transfer batch management responsibilities to a new generation of IT staff with far less hands-on platform experience-without exposing themselves to related risks such as missed batch execution deadlines, missed service level agreements and excess costs.

Safeguarding performance, controlling costs and smooth ownership transfers are more critical than ever given the growing importance of mainframe systems. According to a commissioned study conducted by Forrester Consulting on behalf of Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. And that percentage is expected to increase to 64 percent by 2019. The complete Forrester Opportunity Snapshot report, entitled "Modern Mainframe KPIs Are Key To A Successful Digital Strategy," can be found here.

Batch processing on the mainframe remains critical for many core business functions, such as reconciliation of financial transactions and re-pricing of mutual funds. In many cases, these batch workloads must be completed within a tight time-window. So as the size of a batch workload increases-and as other processing activity consumes an enterprise's finite platform resources-ops staff must take appropriate action. Those actions can include juggling the prioritization of jobs, assigning jobs to alternative LPARs and addressing data dependencies that may be holding up job initiation.

ThruPut Manager empowers IT staff to achieve these operational objectives by:

  • Making it easy to see whether batch jobs are meeting key service metrics-especially how quickly they start executing-and if not, what underlying issues are causing delays or non-initiation.
  • Graphically visualizing how it may be constraining less important workloads to minimize a R4HA peak.
  • Enabling operators to avoid unnecessary R4HA peaks by adaptively shifting workload priorities while still fulfilling business imperatives-rather than limiting them to inflexible "hard-capping."
  • Empowering mainframe ops teams to configure automation rules for initiating batch jobs based on parameters such as business impact, completion windows and workload size.

ThruPut Manager also helps ops teams avoid having too many batch jobs execute at the same time, commonly referred to as "over-initiating," which can cause them to compete for scarce CPU cycles-resulting in extended batch elapsed times and missed schedules, as can happen with IBM's WLM-managed initiators.

"Managing the system utilization and the user's expectations has been a real challenge for us," said Christopher Prenatt, who is the Lead Performance Engineer at Verizon. "The new ThruPut Manager GUI will give us the ability to visualize our batch workload for the first time. We can quickly see how long jobs are sitting in the queue and, if there is a problem, rapidly drill down to what the root cause may be. This will be a great addition for our application teams and ultimately help us get maximum value out of our mainframe."

"As mainframe workloads continue to increase, enterprise IT faces growing challenges in batch execution management," said Rich Ptak of IT analyst firm Ptak Associates. "Compuware ThruPut Manager provides much needed clarity and insight to fine-tune batch execution for optimal value easing budget stresses-even as less-experienced staff take on more mainframe responsibilities."

Compuware today also announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. zAdviser measures application quality, development velocity, and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts.

Today's announcements mark the 14th consecutive quarter that Compuware has announced significant innovation in the modernization and mainstreaming of the mainframe. This innovation is of vital importance to large enterprises that must get maximum business value from their mainframe environments-which are doing double-duty as both self-contained core systems of record, and as powerful back-end data and transaction processing systems for front-end customer-facing web and mobile applications.

"Enterprise CIOs have come to realize that high-cost, high-risk attempts to re-platform their supremely valuable mainframe applications make no sense. The less costly, less risky and higher return strategy is to simply adopt better technology for modernizing on platform and mainstreaming mainframe development, operations and security," said Chris O'Malley, CEO of Compuware. "Compuware is redefining what mainframe modernization means and is committed to delivering what customers need to enable them to adopt the smarter strategy."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum